NO-1886 – 25 mg

Brand:
Cayman
CAS:
133208-93-2
Storage:
-20
UN-No:
Non-Hazardous - /

Lipoprotein lipase (LPL) mediates the hydrolysis of triglycerides in circulating very low density lipoproteins and chylomicrons.{21275,21267} NO-1886 is an LPL activator that increases LPL mRNA and LPL activity in adipose tissue, myocardium, and skeletal muscle.{30942} This coincides with an elevation in post-heparin plasma LPL activity and LPL mass in rats.{30942,30941} NO-1886 decreases plasma triglyceride concentration and increases plasma high-density lipoprotein cholesterol, resulting in inhibited development of atherosclerotic lesions in coronary arteries and aortas of rats and rabbits.{30942,30941}  

 

Available on backorder

SKU: - Category:

Description

An LPL activator that increases LPL mRNA and LPL activity in adipose tissue, myocardium, and skeletal muscle; decreases plasma triglyceride concentration and increases plasma high-density lipoprotein cholesterol, resulting in inhibited development of atherosclerotic lesions in coronary arteries and aortas of rats and rabbits


Formal name: [[4-[[(4-bromo-2-cyanophenyl)amino]carbonyl]phenyl]methyl]-phosphonic acid diethyl ester

Synonyms:  Ibrolipim|Lipoprotein Lipase Activator|LPL Activator|OPF 009

Molecular weight: 451.3

CAS: 133208-93-2

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Activators||Research Area|Cardiovascular System|Cardiovascular Diseases|Atherosclerosis||Research Area|Cardiovascular System|Lipids & Lipoproteins|Lipoproteins||Research Area|Lipid Biochemistry|Sterol Lipids